Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 4

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 3
Chunk 4
---
 complete the development of our current drug candidates or develop other
pharmaceutical products. It is possible that none of them will be successfully commercialized, which would prevent us from ever achieving
profitability.

The group’s ongoing
viability and ability to continue as a going concern depends on its capacity to meet debts and commitments as they fall due. Based on
current budget forecast assumptions, the group is in a position to meet future commitments in the current business cycle and pay its debts
as and when they fall due. Furthermore, the group is able to progress its research and development programs for at least the next 12 months.
In addition, the group has the ability to employ cash management strategies such as delaying or reducing some operating activities and
raise further capital subject to maintaining an active listing on the NASDAQ exchange as well as compliance with the group’s obligations
under ASX Listing Rule 7.1. The group’s track record of successful capital raises provides confidence in their ability to secure funding
if required.

Our research and development activities could be adversely impacted
if our sources of funding and revenue are insufficient

We anticipate that as
the costs related to the development of our clinical trials will increase, we will require additional funds to achieve our long-term
goals of commercialization and further development of our drug candidates. In addition, we will require funds to pursue regulatory
applications, defend intellectual property rights, contract manufacturing capacity, potentially develop marketing and sales
capabilities and fund operating expenses. We intend to seek such additional funding through public or private financings and/or
through licensing of our assets or other arrangements with corporate partners. However, such financing, licensing opportunities or
other arrangements may not be available from any sources on acceptable terms, or at all. Any shortfall in funding could result in us
having to curtail or cease our research and development activities, thereby harming our business, financial condition and results of
operations.

In addition, because of the
numerous risks and uncertainties associated with the development of our drug candidates, we are unable to predict the timing or amount
of increased research and development costs, or when, or if, we will be able to achieve or maintain profitability. Our costs could significantly
increase beyond current expectations if the applicable regulatory authorities require further studies in addition to those currently anticipated.
In any case, even if our drug candidates are approved for commercial sale, we anticipate incurring significant costs associated with the
commercial launch of such drug candidates and there can be no guarantee that we will ever generate significant revenues.

We